» Articles » PMID: 39822170

Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)

Abstract

Gastric cancer is one of the most common cancers in both Korea and worldwide. Since 2004, the Korean Practice Guidelines for Gastric Cancer have been regularly updated, with the 4th edition published in 2022. The 4th edition was the result of a collaborative work by an interdisciplinary team, including experts in gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology, and guideline development methodology. The current guideline is the 5th version, an updated version of the 4th edition. In this guideline, 6 key questions (KQs) were updated or proposed after a collaborative review by the working group, and 7 statements were developed, or revised, or discussed based on a systematic review using the MEDLINE, Embase, Cochrane Library, and KoreaMed database. Over the past 2 years, there have been significant changes in systemic treatment, leading to major updates and revisions focused on this area. Additionally, minor modifications have been made in other sections, incorporating recent research findings. The level of evidence and grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation system. Key factors for recommendation included the level of evidence, benefit, harm, and clinical applicability. The working group reviewed and discussed the recommendations to reach a consensus. The structure of this guideline remains similar to the 2022 version. Earlier sections cover general considerations, such as screening, diagnosis, and staging of endoscopy, pathology, radiology, and nuclear medicine. In the latter sections, statements are provided for each KQ based on clinical evidence, with flowcharts supporting these statements through meta-analysis and references. This multidisciplinary, evidence-based gastric cancer guideline aims to support clinicians in providing optimal care for gastric cancer patients.

Citing Articles

Management Strategy of Non-curative ESD in Gastric Cancer: Curative Criteria, and the Critical Building Block for Determining Beyond It.

Lee H J Gastric Cancer. 2025; 25(1):210-227.

PMID: 39822176 PMC: 11739647. DOI: 10.5230/jgc.2025.25.e5.


A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines: 2024 Update.

Eom S, Ryu K, Han H, Kong S J Gastric Cancer. 2025; 25(1):153-176.

PMID: 39822173 PMC: 11739642. DOI: 10.5230/jgc.2025.25.e10.


Advancing Systemic Therapy in Gastric Cancer: Key Updates From the Korean Practice Guidelines for Gastric Cancer 2024.

Ryu M, Ryu K J Gastric Cancer. 2025; 25(1):1-4.

PMID: 39822169 PMC: 11739644. DOI: 10.5230/jgc.2025.25.e6.

References
1.
Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

2.
Choi Y, Kim H, Shin S, Kim H, Lee J, Yang H . Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg. 2018; 270(2):309-316. DOI: 10.1097/SLA.0000000000002803. View

3.
Wang C, Zhang X, Lin S, Yang C, Zhou B, Mi Y . Superiority of Laparoscopic Gastrojejunostomy Combined With Multimodality Therapy for Gastric Outlet Obstruction Caused by Advanced Gastric Cancer. Front Oncol. 2022; 12:814283. PMC: 8832489. DOI: 10.3389/fonc.2022.814283. View

4.
Hahn K, Park C, Lee Y, Chung H, Park J, Shin S . Comparative study between endoscopic submucosal dissection and surgery in patients with early gastric cancer. Surg Endosc. 2017; 32(1):73-86. DOI: 10.1007/s00464-017-5640-8. View

5.
Hwang J, Park K, Park Y, Lee H, Yoon H, Shin C . A scoring system for patients with a tumor-positive lateral resection margin after endoscopic resection of early gastric cancer. Surg Endosc. 2015; 30(7):2751-8. DOI: 10.1007/s00464-015-4543-9. View